Onconetix, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
Onconetix, Inc. (ONCO) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits of $645.11 thousand as of 2024-12-31, per its 10-K filed 2025-06-02.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense › Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits · last filed 2025-06-02
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $645.11K.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $690.76K.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $308.55K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits |
|---|---|
| 2024-12-31 | $645.11K 10-K · filed 2025-06-02 |
| 2023-12-31 | $690.76K 10-K · filed 2025-06-02 |
| 2022-12-31 | $308.55K 10-K · filed 2024-04-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |